目前,诊断COVID-19的唯一可靠检测方法是RT-qPCR。血清学测定已被广泛用于提高感染人群的检测灵敏度。特此,我们报告了一种新的泛IgG多重酶免疫分析(免疫点)方法的性能,用于探索不同的SARS-COV-2血清学结果。
在罗氏和Snibe平台上,对回收的COVID-19受试者的38份残留血清样本进行了回顾性研究,血清学结果不一致,在新的半自动化泛IgG免疫点酶免疫分析上进行了重新分析,即COVIDOT测试,以找到差异的来源并评估后一种方法。在BlueDiver®仪器上分析所有样品,并且使用D0T®软件通过BlueScan®扫描仪读取所有条带。
根据我们的数据,受试者样本在免疫点条上对≥2种不同抗原显示特异性IgG反应.在这38个样本中,97.4%的样本显示针对S1+S2抗原的特异性IgG反应,89.5%显示抗RBD抗原,在COVIDOT-TEST试剂盒上86.8%的抗S2抗原反应。在73.7%和65.8%的样本中检测到特异性IgG-S1抗原和IgG-N抗原反应,分别。
新的半自动化泛IgG免疫点酶免疫测定方法似乎是一种可靠的检测方法,可用于确认可疑的COVID-19血清学筛查结果。
At present, the only reliable test for COVID-19 diagnosis is RT-qPCR. Serological assays have been widely used to increase the detection sensitivity of infected population. Hereby, we report the performance of a new pan-IgG
multiplex Enzyme Immunoassay (immunodot) method for exploration of discrepant SARS-COV-2 serological results.
A retrospective study on 38 residual serum samples from recovered COVID-19 subjects with discordant serological results on Roche and Snibe platforms, were reanalyzed on a new semi-automated pan-IgG immunodot Enzyme Immunoassay, namely COVIDOT-TEST, in order to find the source of discrepancies and to evaluate the latter method. All samples were analyzed on the BlueDiver® Instrument and all strips were read by the BlueScan® Scanner using Dr DOT® Software.
Based on our data, subject samples showed specific IgG reactions on ≥ 2 different antigens on immunodot strips. Of these 38 samples, 97.4 % of samples showed specific IgG reaction against S1 + S2 antigens, 89.5 % showed against RBD antigen, 86.8 % against S2 antigen reaction on the COVIDOT-TEST kit. Specific IgG-S1 antigen and IgG-N antigen reactions were detected in 73.7 % and 65.8 % of the samples, respectively.
The new semi-automated pan-IgG immunodot Enzyme Immunoassay method appeared to be a reliable assay to confirm suspicious COVID-19 serological screening results.